【News_EN】

2025/06/30

RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)

corporate 【News_EN】

2025/05/20

RevolKa Ltd. Secures 210 million JPY (US$1.4 million) Series A Extension Funding to Advance Therapeutic Programs

corporate 【News_EN】

2025/03/04

RevolKa expanding research projects with Daiichi Sankyo

【News_EN】 collab-EN

2024/08/30

RevolKa announces the closing of ￥250 million series A extension funding to accelerate Drug-Discovery programs

corporate 【News_EN】

2024/08/06

RevolKa Started joint research of a drug discovery program for rare diseases

【News_EN】 collab-EN

2024/07/30

RevolKa launched a drug discovery program for rare diseases

【News_EN】 collab-EN

2024/07/17

RevolKa completed the contract research with SEKISUI CHEMICAL CO., LTD

【News_EN】 collab-EN

2024/05/28

RevolKa Signed Master Service Agreement with Daiichi Sankyo

【News_EN】 collab-EN

2024/04/19

La Jolla Institute for Immunology and RevolKa started a Research Collaboration

【News_EN】 collab-EN

2024/02/19

Presentation movie uploaded at Antibody Engineering & Therapeutics 2023

【News_EN】